Immobilization of HIV‐1 TAT peptide on gold nanoparticles: A feasible approach for siRNA delivery (2020)
Sequence: CGRKKRRQRRR
| Experiment Id | EXP002391 |
|---|---|
| Paper | Immobilization of HIV‐1 TAT peptide on gold nanoparticles: A feasible approach for siRNA delivery |
| Peptide | HIV-1 TAT CPP |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 1–2.5 µg/mL (GNP+CPP) |
| Rna Concentration | 50–100 nM ROR1 siRNA |
| Mixing Ratio | weight ratio GNP+CPP:siRNA = 0.75–3.76 (tested) |
| Formulation Format | gold nanoparticle–peptide conjugate with electrostatically bound siRNA |
| Formulation Components | CTAB-stabilized spherical gold nanoparticles + HIV-1 TAT peptide + ROR1 siRNA |
| Size Nm | 32.00 |
| Zeta Mv | 33.80 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | MDA-MB-231 breast cancer cells |
| Animal Model | |
| Administration Route | cell culture transfection (nanoparticle-mediated) |
| Output Type | gene knockdown, apoptosis induction |
| Output Value | ROR1 and CCND1 mRNA downregulation; ~13% apoptotic cells |
| Output Units | |
| Output Notes | Functional siRNA delivery demonstrated via RT-PCR and Annexin-V/PI apoptosis assay. |
| Toxicity Notes | MTT assay: high cell viability at 1–2.5 µg/mL GNP+CPP; increased cytotoxicity attributable to siRNA-mediated apoptosis. |
| Curation Notes |